![[Jcount.com]](https://www.jcount.com/wp-content/uploads/2014/08/jcount150X50.png)
![[Jcount.com]](https://www.jcount.com/wp-content/uploads/2014/08/jcountstartupslogo1.png)
What does Calhoun Vision do?
Calhoun Vision, is a privately held company which is dedicated to enhancing people’s quality of vision through advanced technology in optics and material science. The company is focused on developing vision correction technologies for post cataract surgery patients. It was started in 1999 by Dr.Daniel Schwartz at UCSF and Dr. Robert Grubbs at Cal Tech. Together they have developed the idea of light adjustable lens, the power of which can be change after implanting it in the eye by the safe, non-invasive light application. The company’s first target was the field of cataract surgery, for eliminating refractive errors following intraocular lens implantation.
How much Calhoun Vision was funded?
Calhoun Vision has raised $52M in Venture round on June 4, 2015 from Longitude Capital, Balance Point Capital Partners, H.I.G. BioVentures and RA Capital Management
Previous funding
$8.5M in Venture round on August 27, 2010
$5.1M in Venture round on October 24, 2011
$12.7M inVenture round on March 20, 2014
$17M in Debt Financing on June 4, 2015 from Longitude Capital, Balance Point Capital Partners, H.I.G. BioVentures and RA Capital Management
What is next for Calhoun Vision?
Calhoun Vision will use this funding for continuing supporting the FDA pre market process and for executing on its strategy for transforming the landscape of cataract surgery for physicians and patients. The financing will be used for strengthening its team and for supporting the company through FDA submission process, executing commercial strategy and advancing the product pipeline.
More about Calhoun Vision
The company was founded in 1999 by Daniel Schwartz. It has its headquarters in Pasadena, CA. After years of extensive lab work and clinical studies of hundreds of patients, the company’s Light Adjustable Lens was introduced commercially into countries of the European Union. Calhoun Vision has completed Phase I and II of the necessary clinical investigation, the III and IV phase has commenced, and all the subjects have been enrolled in the study.
